Lifecore Biomedical (LFCR) EBIT: 2009-2025
Historic EBIT for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $5.3 million.
- Lifecore Biomedical's EBIT rose 147.88% to $5.3 million in Q2 2025 from the same period last year, while for May 2025 it was -$17.2 million, marking a year-over-year decrease of 95.01%. This contributed to the annual value of -$17.2 million for FY2025, which is 94.99% down from last year.
- According to the latest figures from Q2 2025, Lifecore Biomedical's EBIT is $5.3 million, which was up 159.00% from -$9.0 million recorded in Q1 2025.
- In the past 5 years, Lifecore Biomedical's EBIT ranged from a high of $5.3 million in Q2 2025 and a low of -$11.6 million during Q3 2024.
- In the last 3 years, Lifecore Biomedical's EBIT had a median value of -$4.2 million in 2023 and averaged -$3.9 million.
- Its EBIT has fluctuated over the past 5 years, first skyrocketed by 173.94% in 2021, then crashed by 13,302.74% in 2022.
- Quarterly analysis of 5 years shows Lifecore Biomedical's EBIT stood at $3.7 million in 2021, then slumped by 245.04% to -$5.4 million in 2022, then skyrocketed by 72.29% to -$1.5 million in 2023, then tumbled by 32.10% to -$2.0 million in 2024, then soared by 147.88% to $5.3 million in 2025.
- Its last three reported values are $5.3 million in Q2 2025, -$9.0 million for Q1 2025, and -$2.0 million during Q4 2024.